Toujeo is a long-acting insulin that was created by Sanofi. It was approved by the FDA in 2015. Toujeo is very similar to Lantus, another long-acting insulin made by Sanofi. The main difference between the two is that Toujeo has a higher concentration of insulin than Lantus.
Lantus is a long-acting insulin analog that was approved by the FDA in 2000. It is manufactured by Sanofi-Aventis and is available in vials and pre-filled pens. Lantus is indicated for the treatment of diabetes mellitus in adults and children. The recommended dose is 10-100 units/day, given once daily. Lantus has a duration of action of 24 hours and can be given with or without meals. Lantus was developed as a once-daily insulin to provide better glycemic control and fewer hypoglycemic episodes compared to NPH insulin. In clinical trials, Lantus was shown to be more effective than NPH insulin in reducing HbA1c levels and improving glucose control. Lantus is now the most prescribed long-acting insulin in the world and is an important treatment option for patients with diabetes.
The winner is Toujeo Dosing because it is more precise and has a lower risk of hypoglycemia.